[{"id":"0076a7d8-33e2-4731-bb3f-66bf49484be6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04196205","created_at":"2021-01-18T20:27:03.388Z","updated_at":"2024-07-02T16:36:52.602Z","phase":"Phase 1/2","brief_title":"Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas","source_id_and_acronym":"NCT04196205","lead_sponsor":"The First Affiliated Hospital of Nanchang University","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anti-CD19 CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2019-12-12"},{"id":"1ffcd993-f396-4e30-8c11-d2d9037a0fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04194931","created_at":"2021-01-18T20:26:29.259Z","updated_at":"2024-07-02T16:36:52.673Z","phase":"Phase 1","brief_title":"Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma","source_id_and_acronym":"NCT04194931","lead_sponsor":"The First Affiliated Hospital of Nanchang University","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anti-CD19 CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2019-12-11"}]